Enzo Biochem patent upheld by Japanese

Enzo Biochem Inc. (Farmindale, CT) announced that the Japanese Patent Office in an opposition proceeding upheld Enzo's patent No. 2,825,090, which covers a key segment of the company's gene identification technology.

The patent covers an Enzo invention that permits the direct and quantitative measurement of the intensity of any signal and thereby measuring the amount of the DNA present. The patent describes both kits and methods in which the formation of a detectable substance signal in solution indicates the presence and quantity of DNA in the sample. The DNA is attached to a solid surface such as a microplate or a biochip to form an array. When treated with the Enzo reagents, a measurable signal is generated.

"We believe this patent has broad application within the rapidly-growing area of genome research and development, and represents still another significant extension of Enzo's capabilities into broader venues of medicine and science," said Elazar Rabbani, chairman and CEO. "We are highly pleased with the reaffirmation of our patent by the Japanese Patent Office."

Enzo has been awarded approximately 200 patents worldwide, many of which cover proprietary labeling and detection products for gene sequencing and genetic analysis. "This vast patent estate is a major Enzo asset, allowing the company to play an increasingly important role in the rapidly unfolding world of modern day diagnostics and genomics. It is just one aspect of the Company's many strengths," he said. "Upholding of this patent in Japan further validates our extensive and increasingly rewarding research and development efforts conducted over the past two decades and which remains ongoing."

Enzo Biochem is engaged in the research, development, and manufacture of health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic serves to the medical community. The company holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material, which would allow for editing and correcting certain abnormalities in genes.

For more information: Dean Engelhardt, Senior VP, Enzo Biochem Inc., 60 Executive Blvd., Farmingdale, NY 11735. Tel: 516-755-5500. Fax: 516-755-5561.

Edited by Laura DeFrancesco
Managing Editor, Bioresearch Online